Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Aethlon Medical (Nasdaq: AEMD) to Merge Into North Immunology, Form NRTX

Under the terms of the deal, existing North Immunology investors will hold approximately 95.25% of the combined company, while Aethlon Medical (Nasdaq: AEMD) shareholders will retain 4.75%, alongside a contingent value right tied to Aethlon's existing Hemopurifier technology. The financing is intended to provide …

Nitish Kishor | 17 September 2026

Artelo Biosciences (Nasdaq: ARTL) Shows ART27.13 Matches Semaglutide in Preclinical Obesity Model

When ART27.13 was combined with semaglutide, the two therapies together achieved roughly 40% total weight reduction. The effect was primarily concentrated in fat mass, with no impact on weight observed in lean control groups, according to Artelo Biosciences (Nasdaq: ARTL). The company said the …

Nitish Kishor | 17 September 2026

BlossomHill Therapeutics (Nasdaq: BLSM) Posts 45% ORR for OMNI-EGFR Candidate in Resistant NSCLC

The data come with a favorable tolerability profile and FDA Fast Track designation already in hand. BH-30643 is being developed for patients who have progressed on third-generation EGFR inhibitors and developed C797S resistance mutations, a setting where no approved targeted therapies currently exist. BlossomHill …

Nitish Kishor | 17 September 2026

Cellectis (Nasdaq: CLLS) Downgraded by Barclays After CAR-T Portfolio Discontinuation

The downgrade follows Cellectis's (Nasdaq: CLLS) decision to discontinue its clinical CAR-T cell therapy portfolio and redirect resources toward early-stage in vivo gene editing. The shift represents a significant strategic reset for a company that had built its identity around allogeneic CAR-T development.

Nitish Kishor | 17 September 2026

Fate Therapeutics (Nasdaq: FATE) to Detail FT839-101 and FT819 Data at ACR Meeting

Fate Therapeutics (Nasdaq: FATE) will also present updated clinical data from its RECLAIM-LN program evaluating FT819 in systemic lupus erythematosus at ACR from November 6 through 11. Phase 1 data presented at CCR West showed favorable tolerability with reduced conditioning, no Grade 3 or …

Nitish Kishor | 17 September 2026

InMed Pharmaceuticals (Nasdaq: INM) Sees ADAR1 Capital Add to Stake With Open-Market Buys

The additional buying brings ADAR1's total indirect beneficial holdings in InMed Pharmaceuticals (Nasdaq: INM), managed under Daniel Schneeberger, to 892,101 shares. The transactions were disclosed through standard beneficial ownership reporting requirements.

Nitish Kishor | 17 September 2026

Longeveron (Nasdaq: LGVN) Explores Strategic Options After ELPIS II Misses Primary Endpoint

Despite the efficacy miss, Longeveron (Nasdaq: LGVN) noted that laromestrocel demonstrated a favorable safety profile in the trial, with no new safety signals identified in infants with this rare and severe congenital heart condition.

Nitish Kishor | 17 September 2026

MediciNova (Nasdaq: MNOV) Gets Buy Rating From Roth MKM on MN-166 Prospects in ALS and DCM

MN-166 is advancing through Phase 3 testing in amyotrophic lateral sclerosis, a progressive neurodegenerative disease with few treatment options, as well as in degenerative cervical myelopathy, a spinal cord condition. Roth MKM's initiation reflects enthusiasm for MediciNova's (Nasdaq: MNOV) core pipeline asset across both …

Nitish Kishor | 17 September 2026

4 Small-Cap Fintech & BDC Stocks in Focus: BTGO, PSEC, GLAD, WDH

Business Overview:BitGo is a digital-asset infrastructure company offering institutional-grade self-custody wallets, qualified custody, staking, prime brokerage and trading services to crypto-native firms and traditional financial institutions; it began trading on the NYSE in January 2026.

Nitish Kishor | 17 September 2026

4 Small-Cap Biotech Stocks to Watch on NASDAQ: RXRX, SEPN, RIGL, ANIP

Business Overview:Recursion is an AI-driven, clinical-stage biotech that maps biology and chemistry data to accelerate drug discovery and its own therapeutic pipeline, generating most of itsTop Linethrough pharma collaborations rather than product sales.

Nitish Kishor | 17 September 2026
Support

Hi! How can we help you today?

Loading…